MARKETS / NASDAQ / BGMS
NASDAQ · WHOLESALE-DURABLE GOODS, NEC · SMALL CAP

BIO Green MED Solution, Inc. BGMS

19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$747,000
▲ 1637.2% vs FY2024
EPS · FY25
$-6.45
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-128.4%
Net margin · FY25
-401.3%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 747,000.00
Revenue, FY2025 · full 19-year series below
Revenue Net income
0.00050.0010.00150.0020.0-0.02007201020132016201920222025
0.00050.0010.00150.0020.0-0.02016201920222025

The company lost 401 cents on every revenue dollar this year.

Per share
USD -6.45
Diluted EPS, FY2025
EPS
0.40.81.2-6.452007201020132016201920222025
0.40.81.2-6.452016201920222025

The company pays no cash dividend.

Profitability
-128.4%
Return on equity, FY2025
ROE
0.250.50.751-128.4%2007201020132016201920222025
0.250.50.751-128.4%2016201920222025
Operating margin-1128.1%
Net margin-401.3%
Return on assets-48.8%

Each USD of equity lost 128 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−9.1%
+13.5%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.01B
Shares outstanding, FY2025
0.050.012007201020132016201920222025
0.000.012016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 8.2M
total assets, end of FY2025
Total assetsUSD 8.2M
EquityUSD 6.8M
CashUSD 3.5M
Current ratio4.70×

Equity funds 84% of total assets.

History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−6.45
−502.46
−6419.18
−27.24
−2.09
−3.42
−9.84
−0.62
−1.95
−3.50
−5.36
−0.89
−1.28
−1.68
−2.22
−3.64
−0.94
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−128.4
·
−272.6
−79.0
−52.0
−37.6
−58.1
−39.4
−41.5
−71.2
−70.8
−78.0
−53.4
−89.3
−68.6
−104.0
−147.6
−102.7
−41.5
Shares out B
0.01
0.00
0.00
0.00
0.01
0.01
0.00
0.01
0.01
0.00
0.00
0.02
0.02
0.01
0.01
0.05
·
·
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
47 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 2 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed